Mancini M.; Monaldi C.; De Santis S.; Rondoni M.; Papayannidis C.; Sartor C.; Curti A.; Bruno S.; Cavo M.; Soverini S., Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells, «CANCERS», 2022, 14, pp. 738 - 750 [Scientific article]Open Access
Facon T.; San-Miguel J.; Dimopoulos M.A.; Mateos M.-V.; Cavo M.; van Beekhuizen S.; Yuan Z.; Mendes J.; Lam A.; He J.; Ammann E.; Kumar S., Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis (Advances in Therapy, (2022), 39, 5, (1976-1992), 10.1007/s12325-022-02083-8), «ADVANCES IN THERAPY», 2022, 39, pp. 3868 - 3869 [Scientific article]
Dimopoulos M.A.; Moreau P.; Terpos E.; Mateos M.V.; Zweegman S.; Cook G.; Delforge M.; Hajek R.; Schjesvold F.; Cavo M.; Goldschmidt H.; Facon T.; Einsele H.; Boccadoro M.; San-Miguel J.; Sonneveld P.; Mey U., Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001)), «ANNALS OF ONCOLOGY», 2022, 33, pp. 988 - 988 [Scientific article]
Dimopoulos M.A.; Moreau P.; Terpos E.; Mateos M.V.; Zweegman S.; Cook G.; Delforge M.; Hajek R.; Schjesvold F.; Cavo M.; Goldschmidt H.; Facon T.; Einsele H.; Boccadoro M.; San-Miguel J.; Sonneveld P.; Mey U., Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322, «ANNALS OF ONCOLOGY», 2022, 33, pp. 117 - 117 [Scientific article]
Soverini S.; De Santis S.; Martelli M.; Monaldi C.; Castagnetti F.; Gugliotta G.; Papayannidis C.; Mancini M.; Bruno S.; Venturi C.; Machova Polakova K.; Ernst T.; Maar D.; Corner A.; Cavo M., Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia, «LEUKEMIA», 2022, 36, pp. 2250 - 2260 [Scientific article]
Solimando A.G.; Malerba E.; Leone P.; Prete M.; Terragna C.; Cavo M.; Racanelli V., Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche, «FRONTIERS IN ONCOLOGY», 2022, 12, Article number: 973836 , pp. 1 - 17 [Scientific article]Open Access
Donati G.; Zappulo F.; Maietti E.; Scrivo A.; Gasperoni L.; Zamagni E.; Tacchetti P.; Pantani L.; Baraldi O.; Comai G.; Cappuccilli M.; Cavo M.; La Manna G., Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney, «TOXINS», 2022, 14, Article number: 391 , pp. 1 - 13 [Scientific article]Open Access
Bruzzese A.; Derudas D.; Galli M.; Martino E.A.; Rocco S.; Conticello C.; Califano C.; Giuliani N.; Mangiacavalli S.; Farina G.; Lombardo A.; Brunori M.; Rossi E.; Antonioli E.; Ria R.; Zambello R.; Di Renzo N.; Mele G.; Marcacci G.; Pietrantuono G.; Palumbo G.; Cascavilla N.; Cerchione C.; Belotti A.; Criscuolo C.; Uccello G.; Curci P.; Vigna E.; Mendicino F.; Iaccino E.; Mimmi S.; Botta C.; Vincelli D.; Sgherza N.; Bonalumi A.; Cupelli L.; Stocchi R.; Martino M.; Ballanti S.; Gangemi D.; Gagliardi A.; Gamberi B.; Pompa A.; Tripepi G.; Frigeri F.; Consoli U.; Bringhen S.; Zamagni E.; Patriarca F.; De Stefano V.; Di Raimondo F.; Palmieri S.; Petrucci M.T.; Offidani M.; Musto P.; Boccadoro M.; Cavo M.; Neri A.; Morabito F.; Gentile M., Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials, «HEMATOLOGICAL ONCOLOGY», 2022, 40, pp. 704 - 715 [Scientific article]
Usmani S.Z.; Nahi H.; Legiec W.; Grosicki S.; Vorobyev V.; Spicka I.; Hungria V.; Korenkova S.; Bahlis N.J.; Flogegard M.; Blade J.; Moreau P.; Kaiser M.; Iida S.; Laubach J.; Magen H.; Cavo M.; Hulin C.; White D.; De Stefano V.; Lantz K.; O'Rourke L.; Heuck C.; Delioukina M.; Qin X.; Nnane I.; Qi M.; Mateos M.-V., Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma, «HAEMATOLOGICA», 2022, 107, pp. 2408 - 2417 [Scientific article]Open Access
Martello M.; Solli V.; Termini R.; Kanapari A.; Remondini D.; Borsi E.; Poletti A.; Armuzzi S.; Taurisano B.; Vigliotta I.; Mazzocchetti G.; Zamagni E.; Merlotti A.; Tacchetti P.; Pantani L.; Rocchi S.; Rizzello I.; Mancuso K.; Cavo M.; Terragna C., Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2022, 23, Article number: 12450 , pp. 1 - 12 [Scientific article]Open Access
Papayannidis C.; Nanni J.; Cristiano G.; Marconi G.; Sartor C.; Parisi S.; Zannoni L.; Saed R.; Ottaviani E.; Bandini L.; Testoni N.; Baldazzi C.; Solli V.; Ricci P.; Di Giovanni Bezzi C.; Abd-alatif R.; Stanzani M.; Paolini S.; Cavo M.; Curti A., Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents, «EUROPEAN JOURNAL OF HAEMATOLOGY», 2022, 108, pp. 449 - 459 [Scientific article]Open Access
Spicka I.; Moreau P.; Martin T.G.; Facon T.; Martinez G.; Oriol A.; Koh Y.; Lim A.; Mikala G.; Rosinol L.; Yagci M.; Cavo M.; Risse M.-L.; Asset G.; Mace S.; van de Velde H.; Yong K., Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis, «EUROPEAN JOURNAL OF HAEMATOLOGY», 2022, 109, pp. 504 - 512 [Scientific article]Open Access
Facon T.; Moreau P.; Martin T.G.; Spicka I.; Oriol A.; Koh Y.; Lim A.; Mikala G.; Rosinol L.; Yagci M.; Cavo M.; Yong K.; Risse M.-L.; Asset G.; Schwab S.; Martinez G., Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis, «HEMATOLOGICAL ONCOLOGY», 2022, 40, pp. 120 - 129 [Scientific article]Open Access
Richardson P.G.; Perrot A.; San-Miguel J.; Beksac M.; Spicka I.; Leleu X.; Schjesvold F.; Moreau P.; Dimopoulos M.A.; Huang J.S.-Y.; Minarik J.; Cavo M.; Prince H.M.; Malinge L.; Dubin F.; van de Velde H.; Anderson K.C., Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study, «THE LANCET ONCOLOGY», 2022, 23, pp. 416 - 427 [Scientific article]
Mateos M.-V.; Weisel K.; De Stefano V.; Goldschmidt H.; Delforge M.; Mohty M.; Cavo M.; Vij R.; Lindsey-Hill J.; Dytfeld D.; Angelucci E.; Perrot A.; Benjamin R.; van de Donk N.W.C.J.; Ocio E.M.; Scheid C.; Gay F.; Roeloffzen W.; Rodriguez-Otero P.; Broijl A.; Potamianou A.; Sakabedoyan C.; Semerjian M.; Keim S.; Strulev V.; Schecter J.M.; Vogel M.; Wapenaar R.; Nesheiwat T.; San-Miguel J.; Sonneveld P.; Einsele H.; Moreau P., LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma, «LEUKEMIA», 2022, 36, pp. 1371 - 1376 [Scientific article]Open Access
